Immunocore Closes $312.1 Million Aggregate Financing, Makes Public Debut

London – February 23, 2021 – Cooley advised late-stage biotechnology company Immunocore on its $312.1 million aggregate financing, which consisted of a $297.1 million initial public offering of 11,426,280 American Depository Shares, including the full exercise of the underwriters’ option to purchase additional ADSs, and a $15 million concurrent private placement with the Bill & Melinda Gates Foundation. Partners Divakar Gupta, Claire Keast-Butler, Nicola Maguire and Eric Blanchard led the team advising Immunocore.

Goldman Sachs, J.P. Morgan Securities and Jefferies acted as joint book-running managers for the offering.

Immunocore, based in Oxfordshire, England with offices in Conshohocken, Pennsylvania, and Rockville, Maryland, is pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune. The company is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Its ADSs now trade on the Nasdaq Global Select Market under the symbol “IMCR.”

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,100+ lawyers across 16 offices in the United States, Asia and Europe.

Related Contacts
Div Gupta Partner New York
Claire Keast-Butler Partner London
Nicola Maguire Partner London
Eric Blanchard Partner New York
Courtney Thorne Partner Boston
Tom Goodman Partner London
Mark Jones Associate London
Sam Meiklejohn Associate London
Patrick Kavanaugh Associate New York
Harry Calkin Associate London
Charles George Associate London
Natasha Kaye Partner London
Aaron Pomeroy Partner Colorado